Successful treatment of refractory joint contractures caused by sclerodermatous graft versus host disease

被引：9
|
作者：
Kim, J. B. [1 ]
Liakopoulou, E. [2 ]
Watson, J. S. [1 ]
机构：
[1] Wythenshawe Hosp, Dept Plast Surg, Manchester M23 9LT, Lancs, England
[2] Christie Hosp NHS Trust, Dept Haematol, Manchester M20 4BX, Lancs, England
来源：
JOURNAL OF PLASTIC RECONSTRUCTIVE AND AESTHETIC SURGERY | 2008年 / 61卷 / 10期
关键词：
Chronic; Contractures; Cutaneous; Graft versus host disease; Joint; Surgical management;
D O I：
10.1016/j.bjps.2007.03.036
中图分类号：
R61 [外科手术学];
学科分类号：
摘要：
Sclerodermatous or cutaneous chronic graft versus host disease is characterised by deposition of collagen in the skin and possibly other soft tissues, resulting in loss of range of motion and functional capabilities. A patient with refractory joint contractures caused by sclerodermatous graft versus host disease is presented, and the successful surgical management of the case described. (C) 2007 British Association of Plastic, Reconstructive and Aesthetic Surgeons. Published by Elsevier Ltd. All rights reserved.
引用
收藏
页码：1235 / 1238
页数：4
相关论文
共 50 条
  • [31] Management of Graft-Versus-Host Disease
    Stoddard, Jerrad M.
    Plair, Tamera
    Jee, Yvonne H.
    PHYSICIAN ASSISTANT CLINICS, 2016, 1 (03) : 419 - +
  • [32] Response to thalidomide therapy in refractory chronic graft-versus-host disease
    PV Browne
    DJ Weisdorf
    T DeFor
    WJ Miller
    SM Davies
    A Filipovich
    PB McGlave
    NKC Ramsay
    J Wagner
    H Enright
    Bone Marrow Transplantation, 2000, 26 : 865 - 869
  • [33] Response to thalidomide therapy in refractory chronic graft-versus-host disease
    Browne, PV
    Weisdorf, DJ
    DeFor, T
    Miller, WJ
    Davies, SM
    Filipovich, A
    McGlave, PB
    Ramsay, NKC
    Wagner, J
    Enright, H
    BONE MARROW TRANSPLANTATION, 2000, 26 (08) : 865 - 869
  • [34] Adult human mesenchymal stromal cells and the treatment of graft versus host disease
    Herrmann, Richard P.
    Sturm, Marian J.
    STEM CELLS AND CLONING-ADVANCES AND APPLICATIONS, 2014, 7 : 45 - 52
  • [35] Review of Graft-Versus-Host Disease
    Ramachandran, Vignesh
    Kolli, Sree S.
    Strowd, Lindsay C.
    DERMATOLOGIC CLINICS, 2019, 37 (04) : 569 - +
  • [36] FDA Approval Summary: Ruxolitinib for Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease
    Przepiorka, Donna
    Luo, Lola
    Subramaniam, Sriram
    Qiu, Junshan
    Gudi, Ramadevi
    Cunningham, Lea C.
    Nie, Lei
    Leong, Ruby
    Ma, Lian
    Sheth, Christopher
    Deisseroth, Albert
    Goldberg, Kirsten B.
    Blumenthal, Gideon M.
    Pazdur, Richard
    ONCOLOGIST, 2020, 25 (02) : E328 - E334
  • [37] Mycophenolate Mofetil Is Effective and Well Tolerated in the Treatment of Refractory Acute and Chronic Graft-versus-Host Disease
    Akiyoshi Takami
    Kanako Mochizuki
    Hirokazu Okumura
    Hirohito Yamazaki
    Masahide Yamazaki
    Yukio Kondo
    Hidesaku Asakura
    Shinji Nakao
    Satsuki Ito
    Yukio Suga
    International Journal of Hematology, 2006, 83 : 80 - 85
  • [38] Extracorporeal photochemotherapy for the treatment of graft-versus-host disease
    Dall'Amico, R
    Messina, C
    THERAPEUTIC APHERESIS, 2002, 6 (04): : 296 - 304
  • [39] Hydroxychloroquine for the treatment of chronic graft-versus-host disease
    Gilman, AL
    Chan, KW
    Mogul, M
    Morris, C
    Goldman, FD
    Boyer, M
    Cirenza, E
    Mazumder, A
    Gehan, E
    Cahill, R
    Frankel, S
    Schultz, K
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2000, 6 (3A) : 327 - 334
  • [40] Remestemcel-L for the treatment of graft versus host disease
    Locatelli, F.
    Algeri, M.
    Trevisan, V.
    Bertaina, A.
    EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2017, 13 (01) : 43 - 56
12345